Lamberto Andreotti - Bristol-Myers Squibb

Lamberto Andreotti - Bristol-Myers Squibb
Total Compensation: $14.9 million

Details: Andreotti has the distinction of netting the top 10's highest year-to-year pay increase (excepting those who weren't CEOs in 2010), as last year's haul was almost $3.2 million more than the one prior. The majority of his raise was due to a $1.5 million growth in stock awards and a $1.1 million jump in non-equity incentive compensation.

In 2011, despite a drop in sales of some old standbys, BMS ($BMY) saw surprising growth with some of its newer products. Company flagship Plavix faltered a bit, but the drugmaker cashed in on leukemia drug Sprycel, diabetes pill Onglyza and antipsychotic Abilify. And Andreotti is starry-eyed about 2012's potential, despite getting rebuffed on a bid for Amylin ($AMLN). The CEO has plans to boost the company's multi-billion-dollar R&D department, and, living up to its "string of pearls" pedigree, BMS is likely to make some more noise in the M&A realm, too.

Lamberto Andreotti - Bristol-Myers Squibb

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.